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Background: Rapid diagnostic tests (RDTs) are central to fulfilling the WHO’s recommendation for parasitologic
confirmation of all suspected cases of malaria. RDT performance may be compromised when exposed to the high
temperature conditions typical of most malaria endemic regions. However, a systematic method to monitor RDT
quality and performance in endemic countries is lacking at the present time. Current methods to monitor RDT
performance in the field include comparing results from RDTs to diagnoses made by light microscopy and
observing health workers perform tests. These methods are not substitutes for direct quality control. In this study,
the suitability of dried Plasmodium falciparum-infected blood as quality control samples for malaria RDTs was
evaluated.
Methods: Three cultured strains of P. falciparum at 200 and 2,000 parasites/μl were tested on 10 brands of RDT.
After baseline testing to determine initial reactivity, aliquots of parasite-infected blood were air dried, stored at
35°C, room temperature (~25°C) or 4°C for one, four and 12 weeks and were then tested on the 10 RDTs after
rehydration. Extended stability testing of dried blood stored at 4°C was done using P. falciparum strain 3D7 at 1,000
and 2,000 parasites/μl.
Results: All dried blood samples at 2,000 parasites/μl retained reactivity (100% sensitivity) at all three temperatures
and time points for all nine RDT brands that detect histidine-rich protein-2 (HRP2). The dried blood samples with
200 parasites/μl were detected by six of the nine HRP2-based RDTs at all storage temperatures and time points.
The sensitivity for two of the three remaining HRP2-based RDTs was 100% up to four weeks of storage at all
temperatures but dropped to 87.5% at week 12. Of the four RDTs that detect plasmodium lactate dehydrogenase
(pLDH) in a pan-specific manner, alone or in combination with HRP2, the detection of pLDH in samples with
2,000 parasites/μL was 100% for two RDTs and 80% for the other two RDTs. The mean level for detection of pLDH
at 200 parasites/μl was low (29%), with a range of 0% to100%, which was partly attributable to weak initial baseline
reactivity. Reactivity of dried 3D7 at 1,000 and 2,000 parasites/μl stored at 4°C was retained at 100% for up to
52 weeks for both HRP2 and pLDH.
Conclusions: In the absence of native or recombinant positive control antigens, well-standardized P. falciparum-
infected dried blood samples can be used as positive control samples for monitoring RDT performance, particularly
with HRP2-detecting tests.Background
Malaria remains a serious health problem for much of
the global population. Over 200 million cases of Plasmo-
dium falciparum occur annually worldwide for which
prompt treatment is required to prevent death, especially
in children under the age of five. The burden of malaria* Correspondence: maidoo@cdc.gov
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reproduction in any medium, provided the oris highest in sub-Saharan Africa. However, travellers
from malaria non-endemic countries are also at
increased risk of severe disease if exposed to this para-
site. Accurate diagnosis of malaria is critical to adminis-
tering appropriate treatment. In the past, due to the
high prevalence of malaria among febrile patients and
the availability of cheap anti-malarial drugs, malaria was
diagnosed on the basis of clinical symptoms, with only a
small proportion of cases confirmed with laboratory
tests. However, the World Health Organization (WHO)td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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emphasize parasitologic confirmation of all suspected
cases [1]. This decision was made for multiple reasons,
including recent reductions in the incidence of malaria in
many endemic countries [2–5], the spread of parasite
resistance requiring a switch to more expensive artemisinin-
based combination therapy (ACT) and the need to
reduce drug pressure to prevent development and spread
of resistance to ACT.
Traditionally, malaria diagnosis has relied on light
microscopic examination of stained blood smears. How-
ever, the capacity to conduct quality routine malaria
microscopy has been low, resulting in little or no use of
the laboratory to confirm suspected cases and a mistrust
of laboratory test results by clinicians [6,7]. In recent
years, malaria rapid diagnostic tests (RDTs) have been
developed and shown to be comparable or surpass rou-
tine microscopy when the use of quality controlled,
well performing test kits [8] is coupled with adequate
training and carefully designed bench aids [9–12]. RDTs
are simple and can be used by non-laboratory staff
in health facilities and by community health workers
[10–12]. The performance of quality controlled RDTs
and their ease of use by a wide variety of non-laboratory
health workers have also, in part, led to the new WHO
recommendation on parasitologic confirmation of all
suspected cases.
Despite their utility, RDTs have several limitations that
need to be considered prior to their routine use. First,
RDT products from different manufacturers can differ
widely in performance characteristics especially in their
ability to identify low parasite density infections, and
inter-lot variation among some tests from the same
manufacturer have been reported [13]. In addition, RDT
performance can be compromised when tests are stored
for long periods at high temperatures and humidity
typical of most malaria-endemic countries [14]. Ensuring
good manufacturing quality is addressed to an extent by
the RDT product evaluation [13] and pre-procurement
lot testing programmes conducted by the WHO, Foun-
dation for Innovative New Diagnostics (FIND) and US
Centers for Disease Control and Prevention (CDC). Data
from these programmes are available to national malaria
control programmes and are intended to ensure the pur-
chase of quality RDTs from manufacturers. In addition,
the WHO provides criteria for selecting RDTs with dif-
ferent sensitivities at low parasite densities that is based
on malaria endemicity. However, quality control (QC) of
RDTs in the field after delivery remains a major chal-
lenge. No systematic method exists to monitor the per-
formance of RDTs at the point of care. Such RDT
performance monitoring in the field is essential since
tests are affected by storage under conditions not speci-
fied by manufacturers. One method of QC employed inthe field has been to compare results from RDTs to
results from light microscopic examination of stained
blood smears from the same clinical specimen. This is
not an ideal comparison as the two tests detect parasites
differently; RDTs detect parasite antigens by immuno-
chromatographic methods whereas microscopy detects
whole parasites. As a result of this difference and
because parasite antigens, especially HRP2, persist for
several days after parasite clearance, RDT positive tests
could be negative by smear microscopy in cases where
patients have received anti-malarial treatment within a
few days or even weeks of being tested [15,16]. Further-
more, accurate slide reading requires proficient micro-
scopists unavailable in most peripheral health facilities
in sub-Saharan Africa [6,17]. The second method of
observing how well health workers perform RDTs
assures the competence of the health worker only and
not the quality of the test since the reactivity of patient
samples are unknown. Recombinant antigens are being
developed for malaria RDTs [18,19]; however, it is not
clear when such antigens will be available for use in the
field. A method using dried blood spots on filter paper
showed some promise; however, the method was not
simple, requiring elution of blood from filter paper with-
out a clear correlation of parasite density in the eluted
sample to the density in the original sample [20]. In
addition, only one culture-derived parasite was tested on
three RDT brands, which according to the WHO/FIND
Round 2 RDT product testing report had low perform-
ance characteristics. Frozen parasite isolates have been
used however; the need for freezing parasites at tem-
peratures below −70°C makes the method impractical
for most resource-limited malaria endemic settings.
Millions of malaria RDTs are currently being used in
malaria endemic countries without suitable methods for
QC at the point of care. While the field waits for recom-
binant antigens, a simple method of using dried parasi-
tized blood in tubes adapted from a similar method used
for HIV rapid tests [21] was developed for malaria rapid
tests. Here, an evaluation of the method and how it can
be used for malaria RDT QC is reported.
Methods
Rapid diagnostic test choice
RDTs were chosen based on performance in Round 2 of
WHO/FIND/CDC RDT performance evaluations [13]
and their availability for purchase (Table 1). Performance
criteria used for test selection was a panel detection
score (PDS) at 200 parasite/μl of ≥90 for Plasmodium
falciparum. PDS for Plasmodium vivax was not consid-
ered for selection since only P. falciparum samples were
available for this study. Based on the above criterion, 10
RDTs were selected for this study (Table 1). Four of the
tests (RDTs 1, 4, 7 and 9) were specific for P. falciparum
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detecting both HRP2 and P. falciparum-specific pLDH.
Three tests (RDTs 2, 6 and 10) were combination tests
detecting HRP2 and pan- specific pLDH. Two other
combination tests (RDTs 3 and 8) detected P. falciparum
and P. vivax by HRP2 and P. vivax-specific pLDH
respectively. One test (RDT 5) was a combination test
that recognized Plasmodium species by detecting pan-
specific pLDH. The same lot of each RDT kit was used for
all experiments with the exception of RDT 1. For this RDT
the same lot was used for baseline, week 1 and 4 experi-
ments and a different lot used for week 12 experiments.
Dried Plasmodium falciparum-infected blood preparation
Three in vitro-cultured P. falciparum strains, Nigeria
XII, PH 1, and FC27/A3 were used for this study. These
parasites were stored as frozen 50 μl aliquots standar-
dized at 200 or 2,000 parasites/μl. Parasites were at ring
stage development (>95%) and parasite levels were
determined and standardized by established methods
[22]. A 50 μl aliquot of frozen blood at 200 and 2,000
parasites/μl for each of the three P. falciparum strains
was thawed and tested for baseline reactivity. The frozen
vials were thawed at room temperature, mixed briefly
and tested on each of the 10 RDT brands. Replicate ali-
quots were then air dried overnight in a bio-safety cabi-
net. After checking that samples were completely dry,
vials were sealed by tightly closing the vial cap and
stored in a refrigerator set at 4°C, at room temperature
(~25°C) or in a dry incubator set at 35°C. A schematic
diagram of dried blood preparation is shown in Figure 1.
Dried blood rehydration and rapid diagnostic testing
Dried blood pellets in tubes were rehydrated with PBS-
Tween [one sachet of PBS-Tween 20 (SIGMA, USA)





CareStart™ Malaria HRP2/pLDH Pf test 2 Pf
CareStart Malaria HRP2/pLDH (Pf/PAN) COMBO 3 Pf/Pan
CareStart™ Malaria HRP2/PLDH (Pf/Pv) COMBO 3 Pf/Pv
CareStart Malaria HRP2 (Pf) 2 Pf
CareStart Malaria pLDH (PAN) 2 Pan
First Response Malaria Ag Combo (PLDH/HRP2) 3 Pan
First Response Malaria Ag HRP2 2 Pf
SD BIOLINE Malaria Ag Pf/Pv (HRP2/pLDH) 3 Pf/Pv
SD BIOLINE Malaria Ag Pf (HRP2) 2 Pf
SD BIOLINE Malaria Ag Pf/Pan (HRP2/pLDH) 3 Pf/Pan
* Number of bands including controls.
# Panel Detection Score from WHO Malaria RDT Product Testing Round 2.PBS; 0.138 M NaCl; 0.0027 M KCl and 0.05% Tween 20
at a pH of 7.4]. On the day of testing, one vial of each of
the three parasite isolates at 200 and 2,000 parasites/μl
and at each storage temperature was rehydrated with
50 μl (same as initial blood volume before drying) of
PBS-Tween and left at room temperature for a mini-
mum of 1 hr. Samples were then gently mixed with the
use of a micropipette. RDT testing was performed
according to the manufacturer’s instructions for each
brand. The only exception was the use of a micropipette
rather than the test-supplied blood transfer device to
transfer 5 μl of blood from the tube onto the test. Sam-
ples were tested after one, four and 12 weeks of storage.
At each time point, each of the three isolates at 200 and
2,000 parasites/μl was tested for the three storage tem-
peratures (total of 18 tests) except for room
temperature-stored Nigeria XII for weeks 4 and 12 and
PH1 at 2,000 parasites/μl for all temperatures at week 12
and 35°C at week 4. The former was due to a laboratory
error that led to the samples being reconstituted at
week 1 and the latter due to unavailability of sufficient
number of aliquots. For the purposes of this investigation,
a weak reactivity is when a band is distinctly faint when
compared to the control band and required brighter light
and a second reader to confirm the presence of a band.
No densitometry measurements were used to determine
band intensity. Band intensity for initial testing of the
10 RDT brands was scored subjectively. However, a band
intensity scale became available for scoring of test bands
in the extended stability testing and, therefore, an object-
ive “+” scoring system was used. A false negative test was
defined as P. falciparum-infected blood identified as posi-
tive by a test at baseline (before drying) and appearing
as a negative test after drying irrespective of storage
temperature. For combination tests, the HRP2 and pLDH





Access Bio, Inc. G0181 98
Access Bio, Inc. G0131 97
Access Bio, Inc. G0161 90
Access Bio, Inc. G0141 99
Access Bio, Inc. G0111 92
Premier Medical Corporation Ltd II6FRC30 100
Premier Medical Corporation Ltd II3FRC30 100
Standard Diagnostics, Inc. 05FK80 96
Standard Diagnostics, Inc. 05FK50-02-4 97
Standard Diagnostics, Inc. 05FK60-02- 3 96
Dry blood in BSC overnight Make 50µL aliquots 
Rehydrate 1 vial after 
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stand for ≥ 1hour 
C  T 
Test sample for Baseline  
reactivity on RDT 
Figure 1 Schematic diagram for preparing dried blood tubes for malaria RDT QC.
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Sensitivity was calculated using the baseline test result
on a particular test before drying as the reference gold
standard. Therefore sensitivity for dried blood detection
was calculated to be product specific. Furthermore,
because storage temperature appeared not to influence
test results for the 12-week period, sensitivity of dried
blood detection was calculated by combining tests results
from tubes stored at the three storage temperatures. For
combination tests, sensitivity was calculated separately
for the HRP2 (Pf) and pLDH (Pan) bands, independently
for each product that detected these antigens.
Dried blood stability
To determine the stability of dried blood over time, a
panel of samples using P. falciparum clone 3D7 at 1,000
and 2,000 parasites/μl was produced. Cultured 3D7 con-
taining rings or early trophozoite forms were produced
using standard malaria culture procedures. A Giemsa-
stained smear read by three microscopists was used
to determine parasitaemia calculated by the number
of infected cells per 1,000 red blood cells. A Coulter
CounterW (Beckman-Coulter, Brea, California, USA) was
used to determine the number of erythrocytes/μl and
the number of parasites/μl subsequently determined
from the total number of RBCs/μl. Uninfected blood
with a similar haematocrit was used to dilute the cul-
tured parasites to 1,000 and 2,000 parasites/μl. The para-
site dilutions obtained were then tested on RDTs 2,
5 and 10 to determine baseline reactivity and then dis-
tributed into 60 μl aliquots in tubes, dried as described
above and stored at 4°C. At weeks 12, 21, 26, 35, 38, 41,
and 52 following dried-tube preparation, vials at 1,000
and 2,000 parasites/μl were rehydrated with 60 μl
PBS-Tween and tested on RDT 2 for up to 52 weeks andRDT 5 for up to 46 weeks. Testing was also done on RDT
10 for up to 26 weeks for samples with 1,000 parasites/μl
and up to 21 weeks for samples with 2,000 parasites/μl.
RDTs 1, 3 and 7 were also tested only at week 52.
Time series experiments using punctured RDT pouches
To simulate the ability of dried blood to identify faulty
RDTs, an experiment was designed in which two sets
each of RDTs 2 and 5 were stored either at room
temperature (~25°C) or in a humidified incubator set
at 37°C. One set each of RDTs at each storage
temperature had two 8 mm holes punctured on each
side of the test pouch with the desiccant intact. At 2 hrs,
6 hrs, 30 hrs, 2 weeks and 4 weeks, duplicate RDTs
were taken from each set and tested using reconstituted
dried blood (3D7) at 1000 parasites/μl. Punctured tests
stored at room temperature for both RDT2 and RDT5
were not tested at weeks 2 and 4 due to unavailability
of tests.
Results
Rapid diagnostic test brand-specific reactivity
Overall, four of the 10 RDT brands (RDTs 1, 3, 4,
and 8), all HRP2-specific tests, maintained reactivity that
was comparable to baseline with dried blood specimens
at both parasite concentrations of 200 and 2,000 para-
sites/μl held at all storage temperatures and time points
tested (Additional file 1: Supplementary information a, c,
d, h). Two RDT brands (RDT 7 and 9), both HRP2 tests,
also maintained reactivity for all samples at both parasite
concentrations at all temperatures and time points with
the exception of specimens of the PH 1 strain at 200 para-
sites/μl when stored at 35°C for 12 weeks (Additional file
1: Supplementary information g and i). The remaining
four RDT brands (RDT 2, 5, 6 and 10; Additional file 1:
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in 53 of 506 tests (10.5% false negative), shared certain
common characteristics. First, all four tests were combin-
ation tests designed to detect P. falciparum and the other
three human malaria species. Second, with the exception
of Nigeria XII parasites at 2,000 parasites/μl (week 1, RT;
week 4, 35°C and week 12, 35°C) that were non-reactive
with pLDH on RDT 6 (Additional file 1: Supplementary
information f), reactivity was lost only for samples at 200
parasites/μl. In addition, for three of four RDTs that
detected P. falciparum separately from other plasmodium
parasites (HRP2 and pLDH as separate bands), reactivity
was lost for pLDH and not HRP2 for 2 RDTs (RDTs 2
and 10) at the low (200 parasites/μl) parasite density.
However, three samples of PH 1 at 200 parasites/μl were
non-reactive for HRP2 on RDT 6, (Additional file 1:
Supplementary information f). Finally, weak baseline re-
activity of the pLDH band was the single most predictive
factor for loss of reactivity after drying blood. The lat-
ter characteristic is particularly exemplified by RDT 5,
a pLDH only test, in which weak baseline band inten-
sity for all three parasite strains at 200 parasites/μl
was predictive of non-reactivity after drying (Additional
file 1: Supplementary information e).Effect of storage temperature and duration of storage
on dried blood reactivity
Storage temperature did not appear to significantly influ-
ence the reactivity of the dried blood. For RDTs 1, 3, 4
and 8, no loss in reactivity compared to baseline was
observed. In some instances, indications of storage
temperature influencing dried blood reactivity could not
be confirmed. Loss of reactivity for one parasite isolate
stored at 35°C was not associated with a loss of reactivity
for another parasite stored at the same temperature and
length of storage. For example, RDT 5 at week 1, using
dried PH 1 at 200 parasites/μl was non-reactive for sam-
ples stored at 4°C and RT but reactive for the sample
stored at 35°C. At week 12, the same sample was non-
reactive for samples stored at 4°C and 35°C but reactive
for the sample stored at RT. Another example is shown
by parasite strain FC27/A3 at 200 parasites/μl on RDT5.
At week 4, dried blood specimens stored at 4°C and
35°C were non-reactive while that stored at RT was
reactive. Considering the weak baseline reactivity of
both PH 1 and FC27/A3 at 200 parasites/μl on RDT 5,
a pLDH-specific test, it is likely the loss of reactivity was
due to the sample being detected close to the limit of de-
tection of the test and not due to storage temperature. A
stronger indication of an influence of storage temperature
on dried blood reactivity is given by the reactivity of
35°C-stored PH1 at 200 parasites/μl at week 12 on RDTs
7 and 9, both HRP2-specific tests. This was the only non-reactive sample of all parasite/storage temperature/time
combinations for these two RDTs.
Effect of parasite isolate on dried blood reactivity
At comparable parasite densities, similarly stored Nigeria
XII and FC27/A3 but not PH 1 retained their reactivity
on eight of 10 RDTs (RDTs 1, 3, 4, 5, 7, 8, 9 and 10);
implying a parasite-specific reactivity profile. Indeed, at
200 parasites/μl, baseline reactivity for PH 1 was weak
or negative on RDTs 2, 5, 6 and 10. In addition, at
200 parasites/μl, PH 1 reactivity was weak for all storage
temperatures at weeks 1 and 4 and for 4°C and RT at
week 12 on RDT9 (Additional file 1: Supplementary in-
formation i). On RDT 7, weak reactivity was observed
for this sample stored at 4°C for week 1 and for RT and
35°C for both weeks 4 and 12. At week 12, reactivity was
lost for the sample stored at 35°C. In addition to the re-
activity on RDTs 7 and 9, weak reactivity for PH 1 at
200 parasites/μl was observed for several samples on
RDTs 2, 3, 4, 5, 6, 8 and 10.
Sensitivity of dried blood detection
Using the baseline result as the gold standard and com-
bining results from all three parasites and storage condi-
tions, all dried blood at 2,000 parasites/μl retained
reactivity (100% sensitivity) on all nine RDT brands that
detect HRP2 (Table 2). At 2,000 parasites/μl, sensitivity
for pLDH (Pan) for two of four combination tests was
100%. The sensitivities for the two remaining RDTs
(RDTs 2 and 6) were lower at 80%.
At 200 parasites/μl, dried blood stored at all tempera-
tures and time points were detected at 100% sensitivity
on six of nine RDTs for HRP2. The sensitivity on two of
the three remaining HRP2 detecting RDTs was 100% up
to four weeks of storage at all temperatures, dropping to
87.5% for week 12 samples stored at 35°C. The mean
sensitivity of dried blood detection for pLDH was low
(29%, range 0-100%) at 200 parasites/μl. This low sensi-
tivity was partly attributable to weak baseline
reactivity on the pLDH bands on specific RDT brands.
The experiments in this study were not designed to
detect false positivity. Nevertheless, for the two RDTs
specific for both P. falciparum and P. vivax, irrespective
of storage condition, parasite density and length of stor-
age, in no instance was a P. vivax band reactive.
Dried blood stability
Dried 3D7 at 1,000 and 2,000 parasites/μl stored at 4°C
remained reactive after several weeks of storage
(Table 3a). RDT 2 (HRP2/pLDH) was reactive for both
parasite densities for up to 52 weeks irrespective of
the target antigen, although as expected, test band inten-
sities for HRP2 were higher than for pLDH. Because
of the unavailability of additional tests, RDT 5 (pLDH)
Table 2 Sensitivity of detection for dried blood
specimens at different parasite densities and storage
times
Sensitivity
Week 1 Week 4 Week 12
RDT1 200 parasites /μl 100 100 100
2,000 parasites /μl 100 100 100
RDT2 Pf (Pan) 200 parasites /μl 100 (22)† 100 (75)† 100 (12.5)†
2,000 parasites /μl 100 (100) 100 (100) 100 (80)#
RDT3 200 parasites /μl 100 100 100
2,000 parasites /μl 100 100 100
RDT4 200 parasites /μl 100 100 100
2,000 parasites /μl 100 100 100
RDT5 200 parasites /μl 55.5{ 12.5{ 37.5
2,000 parasites /μl 100 100 100
RDT6 Pf (Pan) 200 parasites /μl 89 (67) 100 (33) 75 (0)*
2,000 parasites /μl 100 (89) 100 (86) 100 (80)
RDT7 200 parasites /μl 100 100 87.5#
2,000 parasites /μl 100 100 100
RDT8 200 parasites /μl 100 100 100
2,000 parasites /μl 100 100 100
RDT9 200 parasites /μl 100 100 87.5#
2,000 parasites /μl 100 100 100
RDT10 Pf (Pan) 200 parasites /μl 100 (0 )* 100 (0 )* 100 (33)
2,000 parasites /μl 100 (100) 100 (100) 100 (100)
† Pan band was weakly reactive for two of three parasites at baseline.
{ Weakly reactive for all three parasites at baseline.
* Pan test negative for two of three parasites and weakly reactive for the one
positive parasite at baseline.
# Reactivity lost for one sample stored at 35°C.
Aidoo et al. Malaria Journal 2012, 11:239 Page 6 of 8
http://www.malariajournal.com/content/11/1/239was tested for up to 46 weeks and RDT 10 (HRP2/
pLDH) up to 26 weeks for samples at 1,000 parasites/μl
and up to 21 weeks for samples at 2,000 parasites/μl.
However, at week 52, additional RDT products (RDTs 1, 3
and 7) were positive for both parasite densities (Table 3b).
Dried blood can identify faulty RDTs
The ability of dried blood to identify faulty RDTs was
demonstrated in the time series punctured RDT pouch
tests. In these experiments, intact RDT pouches for both
RDT2 and RDT5 retained their reactivity irrespective of
whether they were stored at room temperature or 37°C
up to the 4 weeks of testing. However, punctured tests
stored at 37°C in a humidified incubator retained
reactivity up to 30 hrs and by week 2 were failing to
show test bands with control bands very faint (additional
file 2: Supplementary information).
Discussion
Malaria RDT performance can be adversely affected by
storage at temperatures above the manufacturer’s recom-
mended range. According to manufacturer-providedproduct specifications, most RDTs require maximum
storage temperatures of approximately 30°C above
which test performance may be compromised, espe-
cially if tests are stored for prolonged periods at such
temperatures. In sub-Saharan Africa, where RDTs are in-
creasingly being used for malaria diagnosis, ambient tem-
peratures are frequently above 30°C and, therefore, in
peripheral health facilities where refrigeration is likely to
be unavailable for cool storage of RDTs, high temperature
exposure is expected to be common. The length of time a
test has to be stored at the higher than the recommended
storage temperatures before performance is affected is
variable. Data from the WHO/FIND/CDC product evalu-
ation indicate [12] most RDTs retain performance after
prolonged periods above required storage temperatures
while some others deteriorate and a minority improve in
performance. It is not clear what level of heat exposure
and for how long a test needs to be exposed for a defini-
tive adverse effect on performance. Therefore, monitoring
RDTs stored under such conditions is critical to an effect-
ive QC system. Such test monitoring could be achieved
by positive controls that are regularly used to test for
RDT performance. Unfortunately, because malaria RDTs
require fresh or frozen parasitized blood and recombi-
nantly produced positive control antigens are as yet
unavailable, field monitoring has largely been ignored as a
component of a comprehensive RDT quality assurance
system. This is despite the importance of guaranteeing
the quality of RDTs especially in peripheral health facil-
ities where they are more likely to be used. In this study,
parasite-infected blood dried in tubes was used as a sim-
ple method for preserving samples for QC of RDTs. The
dried tube method has been successfully used for preserv-
ing samples for HIV antibody detection and was slightly
modified to detect P. falciparum antigens in whole blood.
The use of dried P. falciparum-infected blood as QC
samples appeared to be a feasible method for monitoring
RDT performance. However, these results revealed that,
for country-specific programmes standardization of
the sample on the specific RDT to be monitored is crit-
ical to obtaining desired results. This test-specific
standardization will not be desirable for product evalu-
ation or when several products are being compared,
since one standard will be required for all RDT pro-
ducts. While dried blood retained reactivity on four
RDT brands irrespective of parasite isolate, parasite
density, storage temperature and length of time stored,
reactivity was lost on other RDTs dependent on these
variables. Of note, detection of rehydrated dried blood
by HRP2-specific tests or HRP2-specific test lines on
combination tests was more consistent compared to
pLDH bands. This result is similar to observations
reported in the WHO/FIND/CDC RDT product evalu-
ation that shows HRP2 tests to be more sensitive than
Table 3 Extended stability results for dried Plasmodium falciparum 3D7 infected blood specimens
a)
3D7 PD RDT 5 RDT 2 RDT 10
C T C Pan Pf C Pan Pf
Baseline 1000p/μl ++++ ++++ ++++ ++++ ++++ ++++ ++ ++++
Week 12 ++++ ++ ++++ ++ ++++ ++++ + +++
Week 21 ++++ ++ ++++ ++ ++++ ++++ + +++
Week 26 ++++ ++ ++++ ++ ++++ ++++ + +++
Week 35 ++++ ++ ++++ ++ ++++ ND
Week 38 ++++ ++ ++++ ++ +++ ND
Week 41 ++++ ++ ++++ ++ +++ ND
Week 46 ++++ ++ ++++ ++ +++ ND
Week 52 ND ++++ ++ +++ ND
C T C Pan Pf C Pan Pf
Baseline 2000p/μl ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++
Week 12 ++++ ++++ ++++ +++ ++++ ++++ ++ ++++
Week 21 ++++ ++++ ++++ ++ ++++ ++++ ++ +++
Week 26 ++++ ++++ ++++ ++ +++ ND
Week 35 ++++ ++++ ++++ ++ +++ ND
Week 38 ++++ ++ ++++ ++ +++ ND
Week 41 ++++ ++ ++++ ++ +++ ND
Week 46 ++++ ++ ++++ ++ +++ ND
Week 52 ND ++++ ++ +++ ND
b) 3D7 PD RDT 1 RDT 3 RDT 7
C Pf C PV Pf C T
Week 52 1000p/μl ++++ ++++ ++++ - +++ ++++ +++
2000p/μl ++++ ++++ ++++ - ++++ ++++ ++++
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blood was test-dependent. For instance, at 200 parasites/
μl, all three parasite isolates showed weak reactivity at
baseline on RDT 5, a pLDH only test, while pLDH re-
activity was lost for two of the three parasites on RDTs 6
and 10, both combination tests detecting HRP2 and
pLDH. In addition to test-dependent differences, the
parasite isolate also appeared to influence reactivity.
At 200 parasites/μl, PH 1 was likely being recognized
close to its detection limit, which is conferred by the
amount of HRP2 it produces. Irrespective of storage
temperature and length of storage, PH 1 at this parasite
concentration was associated with more weak or lost
reactivity than the other parasite isolates irrespective of
whether HRP2 or pLDH was the target antigen.
Based on the parasite and test-dependent reactivity
patterns, the use of dried blood requires careful
characterization and standardization of the parasite iso-
late for the type of tests to be monitored. This should
include the use of standard protocols for generation anddilution of validated and quality controlled samples.
Strong baseline reactivity at a required parasite density
may be critical to retaining dried blood reactivity after
rehydration since weak baseline reactivity may suggest
reactivity at the limit of detection of the test and slight
intra-lot variations may result in loss of reactivity on
some tests. Although this study did not identify any clear
temperature-related loss of reactivity of dried blood, the
loss of reactivity of PH 1 at 200 parasites/μl stored only
at 35°C for 12 weeks on RDTs 7 and 9 suggests a pos-
sible temperature effect and therefore prolonged storage
should be at cool temperatures. This has implications
for the practicality of dried blood stored at peripheral
health facilities. One solution could be that dried blood
is stored for shorter times at peripheral health facilities if
refrigeration is unavailable or that supervisors take along
during supervisory visits tubes containing dried samples
stored at cool temperatures at a higher level health facil-
ity. This is supported by the retention of dried 3D7
reactivity for over 12 months. It was also demonstrated
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blood. In addition to their utility as QC samples, dried
blood panels could be developed into proficiency testing
panels for assessing health workers’ ability to perform
RDTs and interpret results. Such a use could double
as assessing the competency of health workers and test
performance at the same time.
Conclusions
In the absence of recombinant positive control antigens,
well-characterized, dried P. falciparum-infected blood in
tubes can be used as QC samples for monitoring the
quality of RDTs. The samples used should be well char-
acterized and standardized for their baseline reactivity
on a range of performance acceptable RDTs. Field test-
ing of this methodology is necessary to assess applicabil-
ity under field conditions.
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